$80.91
-1.26[-1.53%]
At close: Apr 26
$80.91
0[0.00%]
After Hours: 4:35PM EDT
Biomarin Pharmaceutical
(NASDAQ:BMRN)Latest News for Biomarin Pharmaceutical Stock (NASDAQ:BMRN)
Biomarin Pharmaceutical Stock (NASDAQ: BMRN)
Categories: All
Friday, April 26, 2024
Thursday, April 25, 2024
- Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91Benzinga Newsdesk - 2 days ago
- Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - 2 days ago
- Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)Benzinga Insights - 2 days ago
- Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $85Benzinga Newsdesk - 2 days ago
- Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price TargetBenzinga Newsdesk - 2 days ago
- Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $110Benzinga Newsdesk - 2 days ago
- BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.Benzinga Newsdesk - 2 days ago
Wednesday, April 24, 2024
- BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.Benzinga Newsdesk - 3 days ago
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - 3 days ago
- Biomarin Pharmaceutical Raises FY2024 Adj EPS Guidance From $2.60-$2.80 To $2.75-$2.95 Vs $1.65 Est; Affirms FY2024 Sales Guidance from $2.70B-$2.80B Vs $2.77B EstBenzinga Newsdesk - 3 days ago
- Biomarin Pharmaceutical Q1 Adj $0.71 May Not Compare To $0.34 Estimate, Sales $648.83M Miss $651.79M EstimateBenzinga Newsdesk - 3 days ago
Wednesday, April 03, 2024
Thursday, March 21, 2024
Friday, March 08, 2024
Thursday, February 29, 2024
Friday, February 23, 2024
- The Latest Analyst Ratings For Biomarin PharmaceuticalBenzinga Insights - Feb 23, 2024, 1:01PM
- Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $100 Price TargetBenzinga Newsdesk - Feb 23, 2024, 12:18PM
- RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price TargetBenzinga Newsdesk - Feb 23, 2024, 10:47AM
Thursday, February 22, 2024
- Recap: Biomarin Pharmaceutical Q4 EarningsBenzinga Insights - Feb 22, 2024, 4:15PM
- Biomarin Pharmaceutical Q4 2023 Adj EPS $0.49 Beats $0.23 Estimate, Sales $646.20M Beat $636.88M EstimateBenzinga Newsdesk - Feb 22, 2024, 4:04PM
- Earnings Scheduled For February 22, 2024Benzinga Insights - Feb 22, 2024, 5:27AM
Tuesday, February 06, 2024
Tuesday, January 30, 2024
Thursday, December 21, 2023
Tuesday, November 28, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
- Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO ChangeVandana Singh - Nov 7, 2023, 4:12PM
- RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price TargetBenzinga Newsdesk - Nov 7, 2023, 1:09PM
- BioMarin Pharmaceuticals shares are trading higher following a report suggesting activist investor Elliott Investment Management has built a stake in the company and has been in talks with the company for months.Benzinga Newsdesk - Nov 7, 2023, 12:16PM
- Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On TuesdayLisa Levin - Nov 7, 2023, 10:54AM
- 'Activist Investor Elliott Targets Drugmaker BioMarin; Has Spent Over $1B On The Stake In The Co' - Reuters NewsBenzinga Newsdesk - Nov 7, 2023, 10:34AM
Thursday, November 02, 2023
- Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $115Benzinga Newsdesk - Nov 2, 2023, 4:00PM
- BMO Capital Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100Benzinga Newsdesk - Nov 2, 2023, 2:36PM
- Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $117Benzinga Newsdesk - Nov 2, 2023, 12:05PM
- BioMarin Pharmaceutical shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY23 guidance. Additionally, Cantor Fitzgerald and Barclays lowered their respective price targets on the stock.Benzinga Newsdesk - Nov 2, 2023, 11:26AM
- Barclays Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $111Benzinga Newsdesk - Nov 2, 2023, 10:59AM
- Cantor Fitzgerald Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $100Benzinga Newsdesk - Nov 2, 2023, 9:59AM
Wednesday, November 01, 2023
- BioMarin Announces Retirement Of Jean-Jacques Bienaimé; Appoints Alexander Hardy President And Chief Executive OfficerBenzinga Newsdesk - Nov 1, 2023, 5:10PM
- Biomarin Pharmaceutical Sees FY23 Adj. EPS $1.90-$2.05 vs $1.02 Est., Total Revenues $2.39B-$2.47B vs $2.45B Est.Benzinga Newsdesk - Nov 1, 2023, 5:05PM
- Biomarin Pharmaceutical Q3 Adj $0.46 Beats $0.22 Estimate, Sales $581.33M Miss $608.68M EstimateBenzinga Newsdesk - Nov 1, 2023, 5:04PM
- Earnings Scheduled For November 1, 2023Benzinga Insights - Nov 1, 2023, 7:19AM